Who Supplies Calcium to India from DENMARK

To import finished pharmaceutical formulations containing calcium into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application requires submission of Form 40 or 41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing details such as the product's composition, manufacturing process, and stability data. The timeline for obtaining approval varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews. For formulations under HS Code 30049099, specific requirements include compliance with the Drugs and Cosmetics Act, 1940, and adherence to the Drugs and Cosmetics Rules, 1945. The registration ensures that imported formulations meet India's safety, efficacy, and quality standards.

Imported finished pharmaceutical formulations containing calcium must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under India's climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. These measures ensure that imported formulations are safe for consumer use and meet the required quality standards.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, including mandatory registration and licensing for all imported drugs. The Production Linked Incentive (PLI) scheme introduced in 2024 aims to boost domestic manufacturing and may impact the volume of finished formulation imports. Bilateral agreements between India and Denmark have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) standards enhancing the import process for Danish pharmaceutical products.

India imports finished calcium formulations to meet the demand for specialized dosage forms and patented or branded products not manufactured domestically. The domestic market for calcium formulations is substantial, with a total export market of $895.2 million across 996 exporters to 184 countries. However, certain specialized formulations and dosage forms are not produced locally, necessitating imports to fulfill market needs. The import of these formulations ensures a diverse and comprehensive product range for consumers.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on imports. Additionally, a Social Welfare Surcharge (SWS) of 10% is levied on the BCD. This results in a total landed duty of approximately 23.536% for imports of these formulations. These duties are subject to change based on government policies and trade agreements.

Denmark is a significant supplier of high-quality pharmaceutical formulations, including calcium-based products, to India. Danish manufacturers are known for their adherence to stringent quality standards and innovative formulations. While other countries like China, Germany, and the United States also export pharmaceutical products to India, Denmark's reputation for quality and reliability gives it a competitive edge. Denmark's share in India's pharmaceutical import market is notable, reflecting the trust and demand for its products.

India imports calcium formulations from Denmark due to the availability of specialized dosage forms and patented products not manufactured domestically. Danish pharmaceutical companies offer high-quality formulations that meet international standards, fulfilling specific market needs in India. The importation of these products ensures a diverse and comprehensive range of calcium supplements for consumers.

Compared to other sources like China, Germany, and the United States, Denmark offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. Danish manufacturers adhere to stringent quality standards and have a reputation for producing innovative and effective formulations. This positions Denmark favorably in the Indian market, where quality and trust are paramount.

Potential risks for Indian importers include reliance on a single source, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, maintaining adequate inventory levels, and establishing robust quality assurance processes. Regular communication with suppliers and staying informed about regulatory updates are also crucial for minimizing potential disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential shipping delays or demand fluctuations.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory management.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities, quality control processes, and compliance with international standards.

1. 1Obtain Importer Exporter Code (IEC): Register with the Directorate General of Foreign Trade (DGFT) to obtain an IEC.
2. 2Apply for CDSCO Registration: Submit Form 40 or 41 to CDSCO, along with the required documentation.
3. 3Secure Import License: Obtain an import license from CDSCO for the specific product.
4. 4Acquire No Objection Certificate (N